Obstetrical & Gynecological Survey · Nov 5, 2026

Comment on “Effect of Low-Dose Tamoxifen on Benign Gynecological and Breast Conditions in a Phase 3 Trial in Noninvasive Breast Cancer”

By Sankey HZ

There is extensive evidence to date that supports the efficacy of tamoxifen as a preventive therapy in patients at elevated risk of breast cancer; despite this, uptake of this treatment is suboptimal in this population, often due to apprehension about adverse effects and quality of life. Side effects that have shown the greatest rates of concern are menopausal symptoms, endometrial cancer, venous thromboembolism, and stroke. Recently, a deescalation trial was conducted to evaluate the efficacy of low-dose tamoxifen and showed a 52% reduction in recurrence risk and a 75% decrease in contralateral breast events in patients with postsurgical hormone-sensitive ductal carcinoma in situ (DCIS) or high-risk lesions. This has led to broader clinical acceptance, and recent guidelines include low-dose tamoxifen. Previous studies have shown increased risks associated with standard dose tamoxifen in benign gynecological disorders, but this effect has been modulated in the past by menopausal status; menopausal status, however, has not yet been investigated thoroughly as a factor influencing tamoxifen response. This study was a follow-up analysis of a previously published trial of low-dose tamoxifen comparing benign gynecologic and breast events in those taking low-dose tamoxifen (5 mg/d) versus placebo and in pre-menopausal versus postmenopausal patients. The original study was a multicenter, phase 3, double blind, placebo-controlled trial that enrolled 500 patients at high risk of breast cancer who were randomly assigned to receive low-dose tamoxifen or placebo for a 3-year period. A total of 253 were assigned to the tamoxifen group and 247 were assigned to the placebo group. Participants underwent a gynecologic exam and transvaginal ultrasound at baseline and every 12 months for 3 years. Among the participants, 86 were diagnosed with benign gynecologic conditions, with 46 in the tamoxifen group and 40 in the placebo group. Conditions detected included uterine myomas, endometrial polyps, and breast or ovarian lesions. The mean endometrial thickness for premenopausal patients was 4.7 mm in the tamoxifen group and 5.1 mm in the placebo group at baseline, and there was no significant interaction between treatment and time, indicating that endometrial proliferation was not affected by low-dose tamoxifen. For postmenopausal patients, there was an increase in endometrial thickness of 1.5 mm at 36 months in the tamoxifen group ( P <0.001) compared with the placebo group (3.5 to 4.5 mm vs. 3.0 to 3.5 mm), but the difference was small enough to be considered clinically insignificant. Kaplan-Meier analysis showed no differences in time to first benign event, which held true when restricted to uterine conditions. This was also true when analyses were stratified by menopausal status. Similarly, no significant differences were observed for breast conditions in overall or stratified analyses. Site-specific analyses also showed no significant differences. In addition, there were no significant differences in the distribution of benign events based on menopausal status. These results are contrasting with some previous studies, mainly in terms of reported rates of benign conditions, particularly in the placebo group. Though these are different from previously reported results in women taking 20 mg per day of tamoxifen, these results confirm the safety profile of low-dose tamoxifen in terms of gynecologic conditions. Future research should focus on increasing sample size and statistical power to detect rare events, particularly for sub-analyses such as menopausal status. Low-dose tamoxifen presents an opportunity for tailoring cancer treatment to the individual, and this study supports evidence of its safety and efficacy. (Summarized from Carbone A, Oliva M, Puntoni M, et al. Effect of low-dose tamoxifen on benign gynecological and breast conditions in a phase 3 trial in noninvasive breast cancer. J Natl Cancer Inst . 2026;118(6):1115-1119. doi:10.1093/jnci/djaf250).

doi.org/10.1097/ogx.0000000000001664Interventions

AgingResearch.News